Datasheet1_Improving shared decision making for lung cancer treatment by developing and validating an open-source web based patient decision aid for stage I–II non-small cell lung cancer.pdf

The aim of this study was to develop and evaluate a proof-of-concept open-source individualized Patient Decision Aid (iPDA) with a group of patients, physicians, and computer scientists. The iPDA was developed based on the International Patient Decision Aid Standards (IPDAS). A previously published questionnaire was adapted and used to test the user-friendliness and content of the iPDA. The questionnaire contained 40 multiple-choice questions, and answers were given on a 5-point Likert Scale (1–5) ranging from “strongly disagree” to “strongly agree.” In addition to the questionnaire, semi-structured interviews were conducted with patients. We performed a descriptive analysis of the responses. The iPDA was evaluated by 28 computer scientists, 21 physicians, and 13 patients. The results demonstrate that the iPDA was found valuable by 92% (patients), 96% (computer scientists), and 86% (physicians), while the treatment information was judged useful by 92%, 96%, and 95%, respectively. Additionally, the tool was thought to be motivating for patients to actively engage in their treatment by 92%, 93%, and 91% of the above respondents groups. More multimedia components and less text were suggested by the respondents as ways to improve the tool and user interface. In conclusion, we successfully developed and tested an iPDA for patients with stage I–II Non-Small Cell Lung Cancer (NSCLC).

本研究旨在与患者、医师及计算机科学家团队共同开发并评估一款基于国际患者决策辅助标准（IPDAS）的开源个性化患者决策辅助工具（iPDA）。该iPDA的开发过程借鉴了先前发表的调查问卷，并以此测试其用户友好性与内容质量。问卷包含40道多项选择题，答案以5分李克特量表（1-5分，从“强烈不同意”至“强烈同意”）进行评分。此外，我们还对患者进行了半结构化访谈。我们对调查结果进行了描述性分析。iPDA由28位计算机科学家、21位医师及13位患者进行了评估。结果显示，92%（患者）、96%（计算机科学家）和86%（医师）认为iPDA具有价值，而治疗信息的有用性则分别被92%、96%和95%的评价者所认可。此外，92%、93%和91%的受访者认为该工具能够激励患者积极参与治疗。受访者建议增加多媒体组件并减少文本内容，以优化工具和用户界面。综上所述，我们成功开发并测试了一款适用于I-Ⅱ期非小细胞肺癌（NSCLC）患者的iPDA。